Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2195999 | 0.99 | PROKR1 (0.42) | PROKR1KDM4CALDH1A1NLRP3SIGMAR1 | |
| SCHEMBL12420774 | 0.84 | HRH3 (0.53) | ALDH1A1NLRP3CYP2D6HRH3SCN9A | |
| SCHEMBL2196624 | 0.83 | MEN1 (0.47) | PROKR1ALDH1A1HPGDSCN9A | |
| SCHEMBL12420768 | 0.82 | MEN1 (0.47) | ALDH1A1SIGMAR1HRH3PARP1 | |
| SCHEMBL12735909 | 0.81 | HPGD (0.54) | ALDH1A1SIGMAR1CYP2D6HRH3HPGD | |
| SCHEMBL12509165 | 0.81 | ALDH1A1 (0.41) | PROKR1KDM4CALDH1A1CYP2D6HPGD | |
| Hydrochloric Acid SCHEMBL2196700 | 0.81 | MEN1 (0.47) | SIGMAR1HRH3PARP1 | |
| SCHEMBL12420842 | 0.81 | HRH3 (0.43) | HRH3SCN7AKCNH2SCN9A | |
| SCHEMBL2195324 | 0.81 | KDM4C (0.54) | KDM4CALDH1A1 | |
| SCHEMBL25120372 | 0.81 | NAMPT (0.48) | KDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | PROKR1 950/4885KDM4C 448/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.